title: 10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation study.
abstract: Vascular endothelial growth factor (VEGF)-targeted agents are standard therapies for metastatic renal cell carcinoma (mRCC), associated with variable tumor shrinkage. Response Evaluation Criteria in Solid Tumors (RECIST) is of limited utility in this setting, and other imaging changes are sought to reliably predict outcome early. We aim to validate 10% tumor shrinkage as the best early indicator of outcome. Methods. In this institutional review board-approved, Health Insurance Portability and Accountability Act-compliant study, 66 mRCC patients with 165 lesions on clinical trials of VEGF-targeted agents underwent thoracic and abdominal computed tomography at baseline and at first follow-up after therapy. Measurements were performed according to RECIST and tumor shrinkage of ≥10% decrease in sum of the longest diameter (-10%SLD). Correlation with time-to-treatment failure (TTF) and overall survival (OS) were compared and stratified by response to the radiologic criteria. Receiver-operating characteristics (ROC) analysis yielded the optimal threshold change in SLD, defining patients with prolonged survival. Results. More than -10%SLD significantly differentiated responders from nonresponders (median TTF 8.4 vs. 4.1 months, p = .001), whereas partial response by RECIST did not (median TTF 6.9 vs. 5.5 months in responders vs. nonresponders, p = .34). -10%SLD was also significantly predictive of OS (median OS 35.1 vs. 15.0 months in responders vs. nonresponders, p = .003). ROC curve analysis yielded -9.3% in SLD as the optimal threshold for response/no response. Conclusion. Ten percent tumor shrinkage is validated as a reliable early predictor of outcome in mRCC patients receiving VEGF-targeted therapies and may provide a practical measure to guide therapeutic decisions.
authors.affiliation: Department of Imaging, Dana-Farber Cancer Institute, and Department of Radiology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, and Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts, USA; Kidney Cancer Center, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
authors.forename: Katherine M
authors.initials: KM
authors.lastname: Krajewski
authors.forename: Yoko
authors.initials: Y
authors.lastname: Franchetti
authors.forename: Mizuki
authors.initials: M
authors.lastname: Nishino
authors.forename: André P
authors.initials: AP
authors.lastname: Fay
authors.forename: Nikhil
authors.initials: N
authors.lastname: Ramaiya
authors.forename: Annick D
authors.initials: AD
authors.lastname: Van den Abbeele
authors.forename: Toni K
authors.initials: TK
authors.lastname: Choueiri
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000401:mortality; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D058990:Molecular Targeted Therapy / Q000379:methods; D012372:ROC Curve; D066066:Response Evaluation Criteria in Solid Tumors; D012189:Retrospective Studies; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A
keywords: Choi; RECIST 1.0; Renal cell carcinoma; Tumor shrinkage; VEGF-targeted therapy
references.citation: AJR Am J Roentgenol. 2010 Aug;195(2):281-9
references.pmid: 20651182
references.citation: Ann Oncol. 2010 May;21(5):936-41
references.pmid: 19889607
references.citation: J Clin Oncol. 2007 May 1;25(13):1753-9
references.pmid: 17470865
references.citation: N Engl J Med. 2007 Jan 11;356(2):125-34
references.pmid: 17215530
references.citation: Eur Radiol. 2013 Mar;23(3):632-9
references.pmid: 22918564
references.citation: J Urol. 2007 Nov;178(5):1883-7
references.pmid: 17868732
references.citation: Eur J Cancer. 2009 Jan;45(2):228-47
references.pmid: 19097774
references.citation: N Engl J Med. 2007 Jan 11;356(2):115-24
references.pmid: 17215529
references.citation: Br J Cancer. 2010 Mar 2;102(5):803-9
references.pmid: 20145618
references.citation: Urol Oncol. 2012 Sep;30(5):695-703
references.pmid: 21865061
references.citation: Cancer. 2014 Mar 1;120(5):711-21
references.pmid: 24264883
references.citation: N Engl J Med. 2003 Jul 31;349(5):427-34
references.pmid: 12890841
references.citation: Urol Oncol. 2013 Oct;31(7):1283-91
references.pmid: 21956044
references.citation: Curr Oncol Rep. 2012 Aug;14(4):295-306
references.pmid: 22532265
references.citation: Cancer. 2010 Mar 1;116(5):1272-80
references.pmid: 20082451
references.citation: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references.pmid: 10655437
references.citation: Invest New Drugs. 2011 Oct;29(5):1090-3
references.pmid: 20524036
references.citation: J Clin Oncol. 2006 Jan 1;24(1):16-24
references.pmid: 16330672
references.citation: Lancet Oncol. 2013 Feb;14(2):141-8
references.pmid: 23312463
references.citation: J Clin Oncol. 2013 Jan 10;31(2):181-6
references.pmid: 23213094
references.citation: AJR Am J Roentgenol. 2010 Jan;194(1):157-65
references.pmid: 20028918
references.citation: Eur Urol. 2011 May;59(5):856-62
references.pmid: 21306819
references.citation: AJR Am J Roentgenol. 2010 Jun;194(6):1470-8
references.pmid: 20489085